{
  "id": 14626129,
  "title": "OMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorder",
  "url": "https://urgent.news/2026/10/15/omass-therapeutics-collects-310m-to-chase-neurocrine-vertex-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T06:00:59.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/omass-therapeutics-collects-310m-to-chase-neurocrine-vertex-in-genetic-adrenal-disorder/"
  },
  "original_language": "en",
  "account": null,
  "summary": "An Oxford-based drug developer has raised one of the largest private financings for a UK biotech in recent years as it seeks to follow in the footsteps of Neurocrine and Vertex-acquired Crinetics in an endocrinology ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}